Pfizer and biontech provide update on mrna-based combination vaccine program against influenza and covid-19 in individuals 18-64 years of age

New york and mainz, germany, august 16, 2024 — pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced top-line results from their phase 3 clinical trial to evaluate the companies' combined mrna vaccine candidate against influenza and covid-19 in healthy individuals 18-64 years of age. the combination candidate consists of pfizer's mrna-based influenza vaccine candidate with the companies' licensed covid-19 vaccine. the phase 3 trial measured two primary immunogenicity objectives (immunogenicity against sars-cov-2 as well as immunogenicity against influenza a and b), of which one was met. in a separate phase 2 trial, pfizer evaluated trivalent (“tirv”) influenza mrna standalone vaccine candidates which demonstrated robust immunogenicity in individuals 18-64 years of age. the companies are evaluating adjustments to the combination vaccine candidate aimed at improving immune responses against influenza b and will discuss next steps with health authorities.
BNTX Ratings Summary
BNTX Quant Ranking